Skip to main content
SpringerLink
Log in

Effect of Fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects

  • Original Paper
  • Published:
Pharmacy World & Science Aims and scope Submit manuscript

Abstract

Objectives

To study the clinical efficacy of Triclabendazole (TCBZ) on Egyptian patients infected with Fasciola and understand the effect of Fascioliasis on the pharmacokinetics of TCBZ.

Methods

The pharmacokinetics of TCBZ administered as a single oral dose (10 mg/kg) was investigated in both infected and parasite––free Egyptian subjects. After oral administration, TCBZ is metabolized to a sulphone and sulfoxide derivatives. The latter is responsible for the fasciolicidal activity of TCBZ, and it could be used as a marker of drug bioavailability. Blood samples were collected following the oral administration, and TCBZ sulfoxide plasma concentrations were determined by a sensitive and specific HPLC method.

Results

Pharmacokinetic parameters (C max, AUC0–48, t 1/2 and t max) for TCBZ sulfoxide were calculated. In patients; the mean C max was 9.11 ± 1.3 μg/ml, the mean AUC (0–48) was 91 ± 10.5 μg h ml−1, the mean t 1/2 was 7.4 ± 0.6 h, and the t max was 3.0 ± 0.4 h. In normal subjects, the mean C max was 8.48 ± 0.92 μg/ml, the mean AUC(0–48) was 85 ± 6.55 μg h ml−1, the mean t 1/2 was 6.2 ± 0.357 h, and the t max was 3 ± 0.4 h. No significant difference could be detected in the patients as compared to normal subjects, which would suggest that Fascioliasis does not affect any of the studied parameters.

No eggs in faeces could be detected following TCBZ treatment. Also, most of the clinical investigations showed significant decline back to the normal ranges post-treatment which indicates complete curing and high TCBZ efficacy.

Conclusion

Fasioliasis as an infective condition widely spread in Egypt has no significant effect on the pharmacokinetic parameters of the orally administered TCBZ and at the same time it is very effective against the parasite which strongly and safely suggests the use of this medication for the treatment of this infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Laburte C, Mott KE, Hull R, Severne Y. Triclabendazole for fascioliasis: efficacy and tolerability of a single treatment. Infectious diseases and public health. A research and clinical update. In: Angelico M, Rocchi G, editors. Italy: Balaban Publishers; p. 325–333.

  2. Lecaillon JB, Godbillon J, Campestrini J, Naquira C, Miranda L, Pacheco R, Mull R Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol 1998; 45:601–4.

    Article  PubMed  CAS  Google Scholar 

  3. Keiser J, Engels D, Büscher G, Utzinger J Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 2005; 14(12):1513–26.

    Article  PubMed  CAS  Google Scholar 

  4. El-Shazly A, El-Desouky I, El-Feky A A case of ectopic fascioliasis in a farmer from Mansoura City. Dakahlia, Egypt. J Egypt Soc Parasitol 1991; 21:333–5.

    PubMed  CAS  Google Scholar 

  5. Haseeb AN, El-Shazly AM, Arafa MA, Morsy AT A review on Fascioliasis in Egypt. J Egypt Soc Parasitol 2002; 32(1):317–54.

    PubMed  Google Scholar 

  6. Robert W, Tolan RW Fascioliasis, http://www.emedicine.com/ped/topic760.htm. Cited 14-5-2006

  7. Fairweather I Triclabendazole: new skills to unravel an old(ish) enigma. J Helminthol 2005; 79(3):227–34.

    Article  PubMed  CAS  Google Scholar 

  8. Sanyal PK, Gupta AC The efficacy and pharmacokinetics of long––term low––level intraruminal administration of triclabendazole in buffalo with induced fasciolosis. Vet Res Commun 1996; 20:461–8.

    Article  PubMed  CAS  Google Scholar 

  9. Sanyal PK, Gupta AC The efficacy and pharmacokinetics of long-term low- level intraruminal administration of triclabendazole in urea molasses blocks against induced bovine and bubaline fascioliasis. Vet Parasitol 1998; 76(8):57–64.

    Article  PubMed  CAS  Google Scholar 

  10. Sanyal PK, Gupta AC The efficacy and pharmacokinetics of triclabendazole in buffalo with induced fasciolosis. Vet Parasitol 1996; 63(1–2):75–82.

    Article  PubMed  CAS  Google Scholar 

  11. Sanyal PK Pharmacokinetic behaviour of triclabendazole in domestic Ruminants follows single and divided dose administration. J Vet Parasitol 1998; 12(2):89–93.

    Google Scholar 

  12. Boray JC, Crowfoot PD, Strong MB, Allison JR, Schelenbaum M, Von Ornelli M, et al. Treatment of immature and mature Fasciola Hepatica infections in sheep and cattle. Vet Rec 1983; 113:315–7.

    PubMed  CAS  Google Scholar 

  13. Negro A, Alvarez-Bujidos ML, Ortiz AI, Cubria JC, Menedez R, Ordonez D Reversed––phase ion––pair high performance liquid chromatographic determination of triclabendazole metabolites in serum and urine. J Chromatogr 1992; 576:135–141.

    Article  PubMed  CAS  Google Scholar 

  14. Martin LK, Beaver PC Evaluation of Kato-Katz thick smear technique for quantitative diagnosis of helminthes infection. Am J Trop Med Hyg 1968; 17:382.

    PubMed  CAS  Google Scholar 

  15. Hennessy DR, Lacey E, Steel JW, Prichard RK The kinetics of triclabendazole disposition in sheep. J Vet Pharmacol Ther 1987; 10(1):64–72.

    PubMed  CAS  Google Scholar 

  16. Alvinerie M, Galter P Assay of triclabendazole and its main metabolites in plasma by high performance liquid chromatography. J Chromatogr 1986; 374:409–414.

    Article  PubMed  CAS  Google Scholar 

  17. Abd Elbary A, Foda N, El-Gazayerly O, El Khatib M Reversed phase liquid chromatographic determination of vinpocetine in human plasma and its pharmacokinetic application. Anal Letters 2002; 35(6):1041–54.

    Article  Google Scholar 

  18. Lancaster R 1980 Pharmacology in clinical practice. Butterworth – Williams Heinenmann Medical books Ltd, London (UK), p. 44. ISBN 0433190523.

    Google Scholar 

  19. Chen MG, Mott KE Progress in assessment of morbidity due to Fasciola Hepatica infection: a review of recent literature. Trop Dis Bull 1990; 87:1–26.

    Google Scholar 

  20. Kinabo LDB, Bogan JA Pharmacokinetics and efficacy of triclabendazole in goats with induced fasciolosis. J Vet Pharmacol Ther 1988; 11:254–59.

    PubMed  CAS  Google Scholar 

  21. Yadegari D, Talaie H, Massoud J Clinical trial of triclabendazole on human fascioliasis: long term follow-up. Med J Islam Rep Iran 1999; 13:89–91.

    Google Scholar 

  22. Farid Z, Trabbolsi B, Boctor F, Hafez A Unsuccessful use of praziquantel to treat fascioliasis in children. J Infect Dis 1986; 154:920–921.

    PubMed  CAS  Google Scholar 

  23. Farid Z, Kamal M, Waodly J Treatment of acute toxaemic fascioliasis. Trans R Soc Trop Med Hyg 1988; 82:299.

    Article  PubMed  CAS  Google Scholar 

  24. Farid Z, Kamal M, Mansour N Praziquantel and Fasciola Hepatica infection. Trans R Soc Trop Med Hyg 1989; 83:813.

    Article  PubMed  CAS  Google Scholar 

  25. Apt W, Aguilera X, Vega F, Miranda C, Zulantay I, Perez C, Gabor M, Apt P Treatment of human chronic fasciolosis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg 1995; 52(6):532–5.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The authors are thankful to Prof. Dr. Salah El-Banawy, Internal Medicine Department, Medical Research Institute, Alexandria for his medical supervision during the period of this self funded study.

Author information

Authors and Affiliations

  1. Drug Bioavailability Centre, National Organization For Drug Control &Research, Ministry of Health, Cairo, Egypt

    Walid H. El-Tantawy

  2. Department of Pharmaceutics, School of Pharmacy, Beni-sueif University, Beni Sueif, Egypt

    Heba F. Salem

  3. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, El-Kasr, El-P.O. Box 528, Al-Orman 12612, Cairo, Egypt

    Nirmeen A. S. Mohammed Safwat

Authors
  1. Walid H. El-Tantawy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heba F. Salem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nirmeen A. S. Mohammed Safwat
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nirmeen A. S. Mohammed Safwat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

El-Tantawy, W.H., Salem, H.F. & Mohammed Safwat, N.A.S. Effect of Fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects. Pharm World Sci 29, 190–198 (2007). https://doi.org/10.1007/s11096-006-9069-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-006-9069-8

Keywords

Search

Navigation